Neurolixis
🏢 View company profile →3Patents
3Active
3Granted
46Portfolio score
Filing activity: Jun 23, 2017 → Jan 27, 2022
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US10562853B2 | Compounds for treating disorders sensitive to serotoninergic regulation controlled by the 5-HT1A receptors | Chemistry; Metallurgy | 0 | Active |
| US11974992B2 | Use of serotonin 5-HT1A receptor agonists to treat diseases associated with sudden unexpected death in epilepsy | Human Necessities | 0 | Active |
| US11191758B2 | Use of selective serotonin 5-HT1A receptor agonists for treating side-effects of VMAT inhibitors | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.